Menu Back to Committee

Programme Co-Chairs

Susan FordaSusan Forda
Vice President, International Regulatory Affair
Eli Lilly & Company Ltd, United Kingdom

Ian HudsonIan Hudson
Chief Executive
MHRA, United Kingdom

A Message from the Co-chairs

Dear Colleagues,

We are delighted to announce that the 29th Annual DIA EuroMeeting will be held in Glasgow, on 29-31 March 2017.

Glasgow is a world-class city and a celebrated travel destination. Once termed “The city of reality”, more recently Glasgow was voted as “The friendliest city in the world”.

With certainty, global medicine development and patient care has never been more complex. We’re witnessing an evolution of science through the establishment of novel biomarkers and a better understanding of the genetic components of diseases. Still, the attrition rate for medicines in development remains high and the timelines preceding the availability of a new medicine lengthy. Meanwhile, the burden of unmet medical need within society has never been more acute. These are the realities we, in medicine development, regulation, delivery and, often as patients, face.

These complex challenges require collaboration of multiple stakeholders – regulators, clinicians, patients, payers and medicine developers – who are equally resolute to the task. Is there a better venue to host this global call for a cooperative effort than “The friendliest city in the world”?

Indeed, the 2017 DIA EuroMeeting in Glasgow represents an ideal time and setting to discuss the evolving European healthcare environment; to reflect on the outcome of recent changes such as alternative regulatory pathways; and to look ahead at emerging developments, such as how the rise of Big Data might impact medicine development, regulation, access and use.

To this end, we are truly honored to serve as the Program Co-Chairs for this important meeting. The sessions offered this year will cover a wide range of topics for pharmaceuticals, biotechnology and medical products. Planned themes include:

  • The current and potential future impacts of eHealth, mHealth and 'Big Data'
  • The effects of collaborative scientific advice involving multiple stakeholders
  • The evolution of and experience with alternative regulatory and access models
  • Meaningful clinical benefit and value frameworks
  • Operational efficacy of clinical trials and personalised medicines
In closing, mindful of the current realities, yet charged by the collective objective of improving patient care, together with our DIA colleagues, we look forward to collaborating with you during the 29th DIA EuroMeeting in Glasgow.

Program Committee

  • Susan  Forda, PhD
    Susan Forda, PhD Vice President, International Regulatory Affairs
    Eli Lilly & Company Ltd., United Kingdom
  • Ian  Hudson, MD, FFPM, FRCP
    Ian Hudson, MD, FFPM, FRCP Chief Executive
    Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom
  • Dimitrios  Athanasiou, MBA
    Dimitrios Athanasiou, MBA Patient Advocate
    Muscular Dystrophy Association Hellas, Greece
  • Gert  Bos, PhD, MSc
    Gert Bos, PhD, MSc Executive Director & Partner
    Qserve Group B.V., Netherlands
  • Claes  Buxfeldt, MSc
    Claes Buxfeldt, MSc Global Price and Reimbursement Director
    Astrazeneca, Sweden
  • Salah-Dine  Chibout
    Salah-Dine Chibout Global Head Discovery & Investigative Safety/Preclinical Safety Therapeutic Area
    Novartis Pharma AG, Switzerland
  • Gaby L. Danan, MD, PhD
    Gaby L. Danan, MD, PhD Pharmacovigilance Expert
  • Hans-Georg  Eichler, MD, MSc
    Hans-Georg Eichler, MD, MSc Senior Medical Officer
    European Medicines Agency, European Union, United Kingdom
  • Zaide  Frias, PharmD
    Zaide Frias, PharmD Head of Human Medicines Evaluation Division
    European Medicines Agency, European Union, United Kingdom
  • Juan  Garcia-Burgos, MD
    Juan Garcia-Burgos, MD Head of Public Engagement Department (Ad Interim)
    European Medicines Agency, European Union, United Kingdom
  • Martin  Harvey Allchurch, LLM
    Martin Harvey Allchurch, LLM Principal International Affairs Officer
    European Medicines Agency, European Union, United Kingdom
  • Jens  Heisterberg, MD
    Jens Heisterberg, MD Vice President, Regulatory Intelligence
    Novo Nordisk, Denmark
  • Angelika  Joos, MPharm
    Angelika Joos, MPharm Executive Director, Global Regulatory Policy
    MSD (Europe) Inc., Belgium
  • Susanne  Keitel, DrSc, RPh
    Susanne Keitel, DrSc, RPh Director
    European Directorate for the Quality of Medicines & Healthcare (EDQM), France
  • Jürgen  Kübler, PhD
    Jürgen Kübler, PhD Quantitative Scientific Consultant
    QSciCon, Germany
  • Geneviève  Le Visage, PharmD
    Geneviève Le Visage, PharmD Head EU Regulatory Policy
    Novartis Pharma AG, Switzerland
  • Trine B Moulvad, MPharm
    Trine B Moulvad, MPharm Vice President, Regulatory & Pharmacovigilance
    Zealand Pharma, Denmark
  • Ana  Palma, PharmD
    Ana Palma, PharmD Global HTA & Patient Access
    Sobi, Belgium
  • Terje  Peetso
    Terje Peetso Policy Officer, Unit H1
    European Commission, Belgium
  • Agnès  Saint-Raymond, MD
    Agnès Saint-Raymond, MD Head of Portfolio Board
    European Medicines Agency, European Union, United Kingdom
  • Gerhard W Schlueter, DrSc, MSc
    Gerhard W Schlueter, DrSc, MSc Vice President, GRA Specialty Medicine
    Bayer Pharma AG, Germany
  • Steffen  Thirstrup, MD, PhD
    Steffen Thirstrup, MD, PhD Director
    NDA Advisory Services Ltd, United Kingdom
  • Phil  Tregunno
    Phil Tregunno Signal Management Unit Manager
    Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom
  • Hans  van Bruggen, MSc
    Hans van Bruggen, MSc Regulatory Affairs Scientist
    eCTDconsultancy B.V., Netherlands
  • John  Wilkinson
    John Wilkinson Director of Devices
    MHRA, United Kingdom
Load More